Axcella Announces Oral Presentation at 2020 International Conference on Frailty and Sarcopenia Research
March 05 2020 - 8:00AM
Business Wire
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company
focused on leveraging endogenous metabolic modulators (EMMs) to
pioneer a new approach for treating complex diseases and improving
health, today announced that it will give an oral presentation at
the 2020 International Conference on Frailty and Sarcopenia (ICFSR)
in Toulouse, France on March 12, 2020.
During the presentation, Axcella Principal Scientist William
Comb, Ph.D. will describe how data science and physiological
primary cell models are being utilized to interrogate targeted
biologies and design EMM compositions with the potential to
influence multiple pathways simultaneously, using Axcella’s AXA2678
muscle product candidate as a model.
Abstract to be presented:
Title: Development of an in vitro platform to predict and
screen combinations of endogenous metabolic modulators capable of
influencing muscle physiology Location: Hôtel-Dieu
Saint-Jacques, Ballroom 1 Time: March 12, 2020 - 2:45 pm
CET
About Endogenous Metabolic Modulators (EMMs)
EMMs are a broad family of molecules, including amino acids,
that regulate human metabolism. Axcella is developing a range of
novel product candidates that are comprised of multiple EMMs and
their derivatives engineered in distinct combinations and ratios to
simultaneously impact multiple metabolic pathways to modify the
root causes of various complex diseases and improve health.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation FD. Such disclosures
will be included on the company’s website in the “Investors and
News” section. Accordingly, investors should monitor such portions
of the company’s website, in addition to following its press
releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company focused on
leveraging endogenous metabolic modulators (EMMs) to pioneer a new
approach for treating complex diseases and improving health. The
company’s product candidates are comprised of EMMs and their
derivatives that are engineered in distinct combinations and ratios
to simultaneously impact multiple biological pathways. Axcella’s
pipeline includes lead therapeutic candidates for non-alcoholic
steatohepatitis (NASH) and the prevention of recurrent overt
hepatic encephalopathy (OHE). Additional muscle- and blood-related
programs are in earlier-stage development. For more information,
please visit www.axcellahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding the development potential of Axcella’s platform and
product candidates, including the ability of its primary cell
models to interrogate biologies and design EMM compositions,
including AXA2678, with the potential to influence multiple
pathways simultaneously. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward looking
statements contained in this press release, including, without
limitation, those related to the breadth and potential uses of the
company’s pipeline of product candidates, the efficiency of the
company’s discovery and development approach, the clinical
development and safety profile of the company’s product candidates
and their health or therapeutic potential, whether and when, if at
all, the company’s product candidates will receive approval from
the U.S. Food and Drug Administration, or other comparable
regulatory authorities, and for which, if any, indications,
competition from other biotechnology companies, the company’s
liquidity, its ability to successfully develop product candidates
through current and future milestones on the anticipated timeline,
if at all, past results from non-IND clinical studies not being
representative of future results, and other risks identified in the
company’s SEC filings, including Axcella’s Quarterly Report on Form
10-Q and subsequent filings with the SEC. The company cautions you
not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. Axcella disclaims
any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent the company’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date. The company explicitly disclaims any obligation to update any
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200305005065/en/
Company/Investor Contact Jason Fredette
jfredette@axcellahealth.com 857.320.2236 Media Contact Azeem
Zeekrya HDMZ azeem.zeekrya@hdmz.com 312-506-5244
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to Apr 2024